Cargando…

Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood

On-site therapeutic drug monitoring (TDM) is important for providing a quick and accurate dosing to patients in order to improve efficacy and minimize toxicity. Aminoglycosides such as amikacin, gentamicin, and tobramycin are important antibiotics that have been commonly used to treat infections of...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-aqbi, Zaidon T., Yap, Yiing C., Li, Feng, Breadmore, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468438/
https://www.ncbi.nlm.nih.gov/pubmed/30704056
http://dx.doi.org/10.3390/bios9010019
_version_ 1783411434472865792
author Al-aqbi, Zaidon T.
Yap, Yiing C.
Li, Feng
Breadmore, Michael C.
author_facet Al-aqbi, Zaidon T.
Yap, Yiing C.
Li, Feng
Breadmore, Michael C.
author_sort Al-aqbi, Zaidon T.
collection PubMed
description On-site therapeutic drug monitoring (TDM) is important for providing a quick and accurate dosing to patients in order to improve efficacy and minimize toxicity. Aminoglycosides such as amikacin, gentamicin, and tobramycin are important antibiotics that have been commonly used to treat infections of chronic bacterial infections in the urinary tract, lung, and heart. However, these aminoglycosides can lead to vestibular and auditory dysfunction. Therefore, TDM of aminoglycosides is important due to their ototoxicity and nephrotoxicity. Here, we have developed a hot embossed poly (methyl methacrylate) (PMMA) microfluidic device featuring an electrokinetic size and mobility trap (SMT) to purify, concentrate, and separate the aminoglycoside antibiotic drugs amikacin, gentamicin, and tobramycin. These drugs were separated successfully from whole blood within 3 min, with 30-fold lower detection limits compared to a standard pinched injection. The limit of detections (LOD) were 3.75 µg/mL for gentamicin, 8.53 µg/mL for amikacin, and 6.00 µg/mL for tobramycin. These are sufficient to cover the therapeutic range for treating sepsis of 6–10 μg/mL gentamicin and tobramycin and 12–20 μg/mL of amikacin. The device is simple and could be mass produced via embossing or injection molding approaches.
format Online
Article
Text
id pubmed-6468438
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64684382019-04-23 Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood Al-aqbi, Zaidon T. Yap, Yiing C. Li, Feng Breadmore, Michael C. Biosensors (Basel) Article On-site therapeutic drug monitoring (TDM) is important for providing a quick and accurate dosing to patients in order to improve efficacy and minimize toxicity. Aminoglycosides such as amikacin, gentamicin, and tobramycin are important antibiotics that have been commonly used to treat infections of chronic bacterial infections in the urinary tract, lung, and heart. However, these aminoglycosides can lead to vestibular and auditory dysfunction. Therefore, TDM of aminoglycosides is important due to their ototoxicity and nephrotoxicity. Here, we have developed a hot embossed poly (methyl methacrylate) (PMMA) microfluidic device featuring an electrokinetic size and mobility trap (SMT) to purify, concentrate, and separate the aminoglycoside antibiotic drugs amikacin, gentamicin, and tobramycin. These drugs were separated successfully from whole blood within 3 min, with 30-fold lower detection limits compared to a standard pinched injection. The limit of detections (LOD) were 3.75 µg/mL for gentamicin, 8.53 µg/mL for amikacin, and 6.00 µg/mL for tobramycin. These are sufficient to cover the therapeutic range for treating sepsis of 6–10 μg/mL gentamicin and tobramycin and 12–20 μg/mL of amikacin. The device is simple and could be mass produced via embossing or injection molding approaches. MDPI 2019-01-30 /pmc/articles/PMC6468438/ /pubmed/30704056 http://dx.doi.org/10.3390/bios9010019 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Al-aqbi, Zaidon T.
Yap, Yiing C.
Li, Feng
Breadmore, Michael C.
Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood
title Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood
title_full Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood
title_fullStr Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood
title_full_unstemmed Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood
title_short Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood
title_sort integrated microfluidic devices fabricated in poly (methyl methacrylate) (pmma) for on-site therapeutic drug monitoring of aminoglycosides in whole blood
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468438/
https://www.ncbi.nlm.nih.gov/pubmed/30704056
http://dx.doi.org/10.3390/bios9010019
work_keys_str_mv AT alaqbizaidont integratedmicrofluidicdevicesfabricatedinpolymethylmethacrylatepmmaforonsitetherapeuticdrugmonitoringofaminoglycosidesinwholeblood
AT yapyiingc integratedmicrofluidicdevicesfabricatedinpolymethylmethacrylatepmmaforonsitetherapeuticdrugmonitoringofaminoglycosidesinwholeblood
AT lifeng integratedmicrofluidicdevicesfabricatedinpolymethylmethacrylatepmmaforonsitetherapeuticdrugmonitoringofaminoglycosidesinwholeblood
AT breadmoremichaelc integratedmicrofluidicdevicesfabricatedinpolymethylmethacrylatepmmaforonsitetherapeuticdrugmonitoringofaminoglycosidesinwholeblood